Oxidized low-density lipoproteins and their antibodies: Relationships with the reverse cholesterol transport and carotid atherosclerosis in adults without cardiovascular diseases

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1472-1478

  Ferreira, Paolla F C ^a   Zago, Vanessa H S ^a   D'Alexandri, Fabio L ^a   Panzoldo, Natália B ^a   Gidlund, Magnus A ^b   Nakamura, Rui T ^c   Schreiber, Roberto ^a   Parra, Eliane S ^a   Santiago, Fernanda D ^a   Nakandakare, Edna R ^b   Quintão, Eder C R ^b   de Faria, Eliana C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Diagnostic Image Laboratory   (Brazil)

Author keywords

Antibodies against oxidized LDL; Carotid intima media thickness; Cholesteryl ester transfer protein; Hepatic lipase; Oxidized LDL; Phospholipid transfer protein

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTIBODY TITER; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CAROTID ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONCENTRATION (PARAMETERS); CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES; APOLIPOPROTEIN B-100; BIOLOGICAL TRANSPORT; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPASE; LIPOPROTEINS, LDL; LIVER; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; RISK FACTORS;

EID: 84862599545     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.05.020     Document Type: Article

References (49)

1. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
2. Arsenault B.J., Boekholdt S.M., Kastelein J.J. Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol 2011, 8:197-206.
3. Matsuura E., Hughes G.R., Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008, 7:558-566.
4. Mizuno Y., Jacob R.F., Mason R.P. Inflammation and the development of atherosclerosis. J Atheroscler Thromb 2011, 18:351-358.
5. Lopes-Virella M.F., Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol 2010, 134:55-65.
6. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011, 12:204-212.
7. Steinerova A., Racek J., Stozicky F., Zima T., Fialova L., Lapin A. Antibodies against oxidized LDL-theory and clinical use. Physiol Res 2001, 50:131-141.
8. Salonen J.T., Yla-Herttuala S., Yamamoto R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
9. Virella G., Virella I., Leman R.B., Pryor M.B., Lopes-Virella M.F. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993, 23:95-101.
10. Maggi E., Finardi G., Poli M., et al. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993, 4:1119-1122.
11. Tinahones F.J., Gomez-Zumaquero J.M., Garrido-Sanchez L., et al. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Res 2005, 46:452-457.
12. Karvonen J., Paivansalo M., Kesaniemi Y.A., Horkko S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003, 108:2107-2112.
13. Shaw P.X., Horkko S., Tsimikas S., et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001, 21:1333-1339.
14. Lopes-Virella M.F., Hunt K.J., Baker N.L., Lachin J., Nathan D.M., Virella G. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 2011, 60:582-589.
15. Al Gadban M.M., Smith K.J., Soodavar F., et al. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One 2010, 5.
16. Virella G., Atchley D., Koskinen S., Zheng D., Lopes-Virella M.F. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 2002, 105:81-92.
17. Burut D.F., Karim Y., Ferns G.A. The role of immune complexes in atherogenesis. Angiology 2010, 61:679-689.
18. Virella G., Lopes-Virella M.F. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 2008, 200:239-246.
19. Yla-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994, 14:32-40.
20. Yla-Herttuala S., Palinski W., Rosenfeld M.E., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989, 84:1086-1095.
21. Saad A.F., Virella G., Chassereau C., Boackle R.J., Lopes-Virella M.F. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006, 47:1975-1983.
22. Oksjoki R., Kovanen P.T., Lindstedt K.A., Jansson B., Pentikainen M.O. OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol 2006, 26:576-583.
23. van der Zwan L.P., Teerlink T., Dekker J.M., et al. Circulating oxidized LDL: determinants and association with brachial flow-mediated dilation. J Lipid Res 2009, 50:342-349.
24. Shoji T., Nishizawa Y., Fukumoto M., et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000, 148:171-177.
25. Chen H.W., Kuo C.L., Huang C.S., Kuo S.J., Liu C.S. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. Cardiology 2008, 110:252-259.
26. Liu M.L., Ylitalo K., Salonen R., Salonen J.T., Taskinen M.R. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol 2004, 24:1492-1497.
27. Hulthe J., Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 2002, 22:1162-1167.
28. Hulthe J., Bokemark L., Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 2001, 21:101-107.
29. Fukumoto M., Shoji T., Emoto M., Kawagishi T., Okuno Y., Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000, 20:703-707.
30. Taylor A.J., Bots M.L., Kastelein J.J. Vascular disease: meta-regression of CIMT trials-data in, garbage out. Nat Rev Cardiol 2011, 8:128-130.
31. Nauck M., Marz W., Jarausch J., et al. Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. Clin Chem 1997, 43:1622-1629.
32. Zaratin A., Gidlund M., Boschcov P., Castilho L., de Faria E.C. Antibodies against oxidized low-density lipoprotein in normolipidemic smokers. Am J Cardiol 2002, 90:651-653.
33. Ehnholm C., Kuusi T. Preparation, characterization, and measurement of hepatic lipase. Methods Enzymol 1986, 129:716-738.
34. Lagrost L. Determination of the mass concentration and the activity of the plasma cholesteryl ester transfer protein (CETP). Methods Mol Biol 1998, 110:231-241.
35. Damen J., Regts J., Scherphof G. Transfer of [14C]phosphatidylcholine between liposomes and human plasma high density lipoprotein. Partial purification of a transfer-stimulating plasma factor using a rapid transfer assay. Biochim Biophys Acta 1982, 712:444-452.
36. Simons P.C., Algra A., Bots M.L., Grobbee D.E., van der Graaf Y. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999, 100:951-957.
37. Boizel R., Benhamou P.Y., Lardy B., Laporte F., Foulon T., Halimi S. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 2000, 23:1679-1685.
38. Castelli W.P. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol 1988, 4(Suppl. A):5A-10A.
39. Ishigaki Y., Oka Y., Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol 2009, 20:363-369.
40. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
41. Wang Y., Fang X., Wang S., Feng Y., Yin J. Relation between plasma oxLDL antibodies and oxLDL in the circulation. Inflammation 2007, 30:7-13.
42. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128:262-269.
43. Oliveira H.C., de Faria E.C. Cholesteryl ester transfer protein: the controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life 2011, 63:248-257.
44. Castilho L.N., Oliveira H.C., Cazita P.M., de Oliveira A.C., Sesso A., Quintao E.C. Oxidation of LDL enhances the cholesteryl ester transfer protein (CETP)-mediated cholesteryl ester transfer rate to HDL, bringing on a diminished net transfer of cholesteryl ester from HDL to oxidized LDL. Clin Chim Acta 2001, 304:99-106.
45. Quintao E.C., Cazita P.M. Lipid transfer proteins: past, present and perspectives. Atherosclerosis 2010, 209:1-9.
46. Yang X.P., Yan D., Qiao C., et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003, 23:1601-1607.
47. Roosbeek S., Vanloo B., Duverger N., et al. Three arginine residues in apolipoprotein A-I are critical for activation of lecithin:cholesterol acyltransferase. J Lipid Res 2001, 42:31-40.
48. Ramsamy T.A., Neville T.A., Chauhan B.M., Aggarwal D., Sparks D.L. Apolipoprotein A-I regulates lipid hydrolysis by hepatic lipase. J Biol Chem 2000, 275:33480-33486.
49. Connelly P.W., Hegele R.A. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 1998, 35:547-572.